About
Bringing Human Cancer Vaccine Science to Dogs
Personalised mRNA cancer vaccines are transforming human oncology. We exist to make that same science available for dogs — today, not in ten years.
The Problem We're Solving
One in four dogs develops cancer. For dogs over ten, it's one in two. Cancer is the leading cause of death in older dogs — and for most of them, the treatment options haven't fundamentally changed in decades. Surgery, chemotherapy, radiation. The outcomes are modest. The side effects are severe. And when those fail, the standard of care is palliative: manage the pain, maintain comfort, wait.
Meanwhile, in human medicine, something remarkable is happening. Personalised mRNA cancer vaccines — designed from each patient's own tumour mutations — are showing results that oncologists call unprecedented. A 49% reduction in melanoma recurrence. Patients with pancreatic cancer and breast cancer disease-free after six years. More than 150 clinical trials underway.
The science works. The manufacturing infrastructure exists. The computational tools are mature. But none of it was being applied to the animals that need it.
That's the gap we fill.
What We Actually Do
We coordinate the entire pipeline for personalised mRNA cancer vaccines for dogs. Your vet takes a tumour biopsy. We handle everything from there — genomic sequencing, computational analysis, neoantigen prediction, vaccine design, mRNA manufacturing, quality control, and cold-chain delivery back to your vet. The vaccine is administered as a simple injection.
We don't own labs. We don't manufacture drugs. We don't replace your veterinarian. We connect proven science to the dogs that need it, through a pipeline that turns a tumour biopsy into a personalised vaccine in 4–6 weeks.
Every tool in our pipeline comes from human precision oncology — the same sequencing, the same variant analysis, the same prediction algorithms, the same mRNA platform used in billions of human vaccine doses. We've adapted it for canine genomics and validated it against published canine cancer datasets.
Based in Switzerland
Switzerland offers a regulatory framework that makes this possible today. Under the Formula magistralis provision, a veterinarian can prescribe a personalised vaccine for a specific animal, manufactured by an authorised facility, without the years-long drug approval process that applies in most countries. This is the same framework that has always governed veterinary compounding — applied to modern science.
Switzerland also puts us at the centre of European mRNA manufacturing, with world-class veterinary medicine at the Universities of Bern and Zurich, and efficient cold-chain logistics across the continent.
How We Operate
Honesty over hype
This treatment will not cure every dog. We tell you that upfront. If your dog's tumour profile suggests the vaccine is unlikely to help, we'll tell you before you spend money — not after. The response rate data is on our website because you deserve to make an informed decision.
Every case makes the next one better
Every dog we treat generates data — which mutations were targeted, which vaccine design was used, and whether the tumour responded. That data improves the prediction accuracy for every future patient. The more dogs treated, the better the science gets.
Your vet stays in charge
We provide the vaccine. Your veterinary oncologist decides the treatment plan, prescribes the vaccine, and administers it. We support them — with patient selection guidance, genomic analysis reports, and follow-up templates — but clinical decisions stay with the clinician who knows your dog.
Team
We are scientists, animal lovers, and entrepreneurs based in Switzerland — united by the conviction that dogs with cancer deserve access to the best science available. Our team combines computational biology, mRNA therapeutics, veterinary oncology, and operational experience to deliver personalised cancer vaccines that work.
Interested in joining or advising? Get in touch.
Have Questions?
Whether you're a dog owner, a veterinarian, or just curious about the science — we're happy to talk.